LBA36 Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebo-controlled, phase III trial

• DOI: 10.1016/j.annonc.2023.10.030
• Publication Date: 2023-10-20T13:21:09Z
• Authors: X. Wu; J. Liu; X. Wang; J. Wang; L. Wang; J. Zhu; B. Kong; J. Fei; Y. Tang; B. Xia; Z. Liang; K. Wang; Z. Lin; Y. Huang; H. Zheng; A. Lin; K. Jiang; W. Wang; X. Wang; G. Lou
• Keywords: Clinical endpoint; Discontinuation; BRCA Mutation